Copyright
©The Author(s) 2021.
World J Gastroenterol. Nov 14, 2021; 27(42): 7285-7298
Published online Nov 14, 2021. doi: 10.3748/wjg.v27.i42.7285
Published online Nov 14, 2021. doi: 10.3748/wjg.v27.i42.7285
Figure 1 “Rebalanced” Hemostasis in patients with liver dysfunction.
AT: Antithrombin; ADAMTS13: a disintegrin and metalloprotease with thrombospondin type I repeats-13; α2AP: α2-antiplasmin; PAI-1: Plasminogen activator inhibitor-1; PDFs: Fibrin degradation products; PC: Protein C; PS: Protein S; TAFI: Thrombin-activatable fibrinolysis inhibitor; t-PA: Tissue plasminogen activator; VWF: Von Willebrand factor.
- Citation: Nguyen G, Lejeune M, Crichi B, Frere C. Hemostasis testing in patients with liver dysfunction: Advantages and caveats. World J Gastroenterol 2021; 27(42): 7285-7298
- URL: https://www.wjgnet.com/1007-9327/full/v27/i42/7285.htm
- DOI: https://dx.doi.org/10.3748/wjg.v27.i42.7285